Q3 EPS Forecast for Janux Therapeutics Raised by Analyst

Key Points

• HC Wainwright has upgraded its earnings estimates for Janux Therapeutics, predicting Q3 2025 earnings per share of ($0.58), an improvement from previous estimates of ($0.63).
• Raymond James Financial initiated coverage on Janux Therapeutics with an "outperform" rating and a target price of $65.00.
• Janux Therapeutics' stock increased by 7.1% recently, with a current market capitalization of $1.46 billion.

Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) - Research analysts at HC Wainwright boosted their Q3 2025 EPS estimates for Janux Therapeutics in a research note issued to investors on Monday, August 11th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of ($0.58) per share for the quarter, up from their prior estimate of ($0.63). The consensus estimate for Janux Therapeutics' current full-year earnings is ($1.38) per share. HC Wainwright also issued estimates for Janux Therapeutics' Q4 2025 earnings at ($0.72) EPS, FY2025 earnings at ($2.21) EPS, Q1 2026 earnings at ($0.75) EPS, Q2 2026 earnings at ($0.77) EPS, Q3 2026 earnings at ($0.77) EPS, Q4 2026 earnings at ($0.71) EPS, FY2026 earnings at ($2.98) EPS, FY2027 earnings at ($2.82) EPS and FY2028 earnings at ($0.94) EPS.

Separately, Raymond James Financial initiated coverage on Janux Therapeutics in a report on Friday, July 11th. They set an "outperform" rating and a $65.00 target price for the company. One equities research analyst has rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $91.89.

Janux Therapeutics Price Performance

Shares of JANX traded up $0.14 during mid-day trading on Wednesday, hitting $25.11. 527,337 shares of the company's stock were exchanged, compared to its average volume of 895,949. The company has a market cap of $1.51 billion, a PE ratio of -13.95 and a beta of 2.86. Janux Therapeutics has a 52 week low of $21.97 and a 52 week high of $71.71. The company has a 50-day simple moving average of $24.61 and a 200 day simple moving average of $28.32.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.07).

Institutional Trading of Janux Therapeutics

Several hedge funds have recently modified their holdings of the stock. Tower Research Capital LLC TRC boosted its position in Janux Therapeutics by 175.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 3,928 shares of the company's stock valued at $91,000 after buying an additional 2,502 shares during the last quarter. Lazard Asset Management LLC boosted its stake in Janux Therapeutics by 64.8% in the 2nd quarter. Lazard Asset Management LLC now owns 99,858 shares of the company's stock worth $2,306,000 after purchasing an additional 39,278 shares during the period. Engineers Gate Manager LP grew its holdings in shares of Janux Therapeutics by 115.0% during the 2nd quarter. Engineers Gate Manager LP now owns 39,749 shares of the company's stock valued at $918,000 after acquiring an additional 21,258 shares in the last quarter. BNP Paribas Financial Markets lifted its stake in shares of Janux Therapeutics by 185.1% in the 2nd quarter. BNP Paribas Financial Markets now owns 7,673 shares of the company's stock valued at $177,000 after purchasing an additional 4,982 shares during the last quarter. Finally, Bank of America Corp DE lifted its position in Janux Therapeutics by 14.7% during the 2nd quarter. Bank of America Corp DE now owns 859,423 shares of the company's stock worth $19,853,000 after acquiring an additional 110,097 shares during the last quarter. 75.39% of the stock is currently owned by institutional investors and hedge funds.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.